Esoform has been acquired by Ecolab
December 2011 — The family owners of Esoform have sold the company to Ecolab for an undisclosed consideration.
Esoform is active in the study, development, production and commercialization of disinfectants, infection prevention and personal care solutions. The company is a leading player in the Italian hospital market with a presence in pharmacies and the mass market.
Ecolab, based in the US, is the global leader in water, hygiene and energy technologies and services that provide and protect clean water, safe food, abundant energy and healthy environments. With this transaction Ecolab plans to expand its healthcare business into Europe, using the Esoform manufacturing plant as the production hub for the region.
Our role in the transaction
Oaklins' team in Italy advised Esoform on the exit strategy and conducted negotiations with potential buyers throughout the transaction. Through a series of bids, the team optimized their proceeds and obtained a remarkable multiple from Ecolab.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more